NYSE:DPLO - Diplomat Pharmacy Stock Price, News & Analysis

$5.50
-0.02 (-0.36 %)
(As of 09/19/2019 01:17 PM ET)
Today's Range
$5.34
Now: $5.50
$5.50
50-Day Range
$4.86
MA: $5.65
$6.60
52-Week Range
$4.17
Now: $5.50
$21.48
Volume26,636 shs
Average Volume779,366 shs
Market Capitalization$417.07 million
P/E Ratio27.45
Dividend YieldN/A
Beta1.01
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. Read More…

Industry, Sector and Symbol

Industry Drug stores & proprietary stores
Sub-IndustryN/A
SectorRetail/Wholesale
CUSIPN/A
Phone888-720-4450

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.49 billion
Cash Flow$4.5082 per share
Book Value$6.24 per share

Profitability

Net Income$-302,270,000.00

Miscellaneous

Employees2,335
Market Cap$417.07 million
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable

Receive DPLO News and Ratings via Email

Sign-up to receive the latest news and ratings for DPLO and its competitors with MarketBeat's FREE daily newsletter.


Diplomat Pharmacy (NYSE:DPLO) Frequently Asked Questions

What is Diplomat Pharmacy's stock symbol?

Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."

How were Diplomat Pharmacy's earnings last quarter?

Diplomat Pharmacy Inc (NYSE:DPLO) posted its quarterly earnings results on Friday, August, 9th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by $0.01. The firm had revenue of $1.29 billion for the quarter, compared to the consensus estimate of $1.23 billion. Diplomat Pharmacy had a negative return on equity of 4.01% and a negative net margin of 8.93%. Diplomat Pharmacy's quarterly revenue was down 9.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.05) EPS. View Diplomat Pharmacy's Earnings History.

When is Diplomat Pharmacy's next earnings date?

Diplomat Pharmacy is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Diplomat Pharmacy.

What guidance has Diplomat Pharmacy issued on next quarter's earnings?

Diplomat Pharmacy updated its FY19 earnings guidance on Friday, August, 9th. The company provided earnings per share (EPS) guidance of ($2.69-2.55) for the period, compared to the Thomson Reuters consensus EPS estimate of ($0.54). The company issued revenue guidance of $4.7-5.0 billion, compared to the consensus revenue estimate of $4.91 billion.

What price target have analysts set for DPLO?

14 equities research analysts have issued twelve-month price objectives for Diplomat Pharmacy's stock. Their forecasts range from $4.00 to $30.00. On average, they anticipate Diplomat Pharmacy's stock price to reach $9.6538 in the next year. This suggests a possible upside of 77.5% from the stock's current price. View Analyst Price Targets for Diplomat Pharmacy.

What is the consensus analysts' recommendation for Diplomat Pharmacy?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diplomat Pharmacy in the last year. There are currently 3 sell ratings, 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Diplomat Pharmacy.

Has Diplomat Pharmacy been receiving favorable news coverage?

Media coverage about DPLO stock has been trending negative on Thursday, according to InfoTrie. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Diplomat Pharmacy earned a daily sentiment score of -2.9 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Diplomat Pharmacy.

Who are some of Diplomat Pharmacy's key competitors?

What other stocks do shareholders of Diplomat Pharmacy own?

Who are Diplomat Pharmacy's key executives?

Diplomat Pharmacy's management team includes the folowing people:
  • Mr. Brian Thomas Griffin, CEO & Chairman (Age 60)
  • Mr. Philip R. Hagerman, Co-Founder & Chairman Emeritus (Age 67)
  • Mr. Daniel Paul Davison, CFO & Treasurer
  • Mr. Dave Loschinskey, Chief Operating Officer (Age 48)
  • Ms. Terri Anne Powers, VP of Investor Relations

Who are Diplomat Pharmacy's major shareholders?

Diplomat Pharmacy's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.07%), Stephens Inc. AR (8.83%), Vanguard Group Inc. (7.64%), JPMorgan Chase & Co. (1.94%), Northern Trust Corp (1.72%) and Invesco Ltd. (1.63%). Company insiders that own Diplomat Pharmacy stock include Atul Kavthekar, Jeffrey G Park, Joel Saban, Kenneth O Klepper, Philip R Hagerman and Shawn Tomasello. View Institutional Ownership Trends for Diplomat Pharmacy.

Which major investors are selling Diplomat Pharmacy stock?

DPLO stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Trexquant Investment LP, Wells Fargo & Company MN, Cubist Systematic Strategies LLC, Voloridge Investment Management LLC, Morgan Stanley, Kings Point Capital Management and Comerica Bank. Company insiders that have sold Diplomat Pharmacy company stock in the last year include Atul Kavthekar and Kenneth O Klepper. View Insider Buying and Selling for Diplomat Pharmacy.

Which major investors are buying Diplomat Pharmacy stock?

DPLO stock was purchased by a variety of institutional investors in the last quarter, including Stephens Inc. AR, JPMorgan Chase & Co., BlackRock Inc., Invesco Ltd., D. E. Shaw & Co. Inc., Charles Schwab Investment Management Inc., Vanguard Group Inc. and Renaissance Technologies LLC. Company insiders that have bought Diplomat Pharmacy stock in the last two years include Atul Kavthekar, Jeffrey G Park and Joel Saban. View Insider Buying and Selling for Diplomat Pharmacy.

How do I buy shares of Diplomat Pharmacy?

Shares of DPLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Diplomat Pharmacy's stock price today?

One share of DPLO stock can currently be purchased for approximately $5.4379.

How big of a company is Diplomat Pharmacy?

Diplomat Pharmacy has a market capitalization of $412.36 million and generates $5.49 billion in revenue each year. The company earns $-302,270,000.00 in net income (profit) each year or $0.20 on an earnings per share basis. Diplomat Pharmacy employs 2,335 workers across the globe.View Additional Information About Diplomat Pharmacy.

What is Diplomat Pharmacy's official website?

The official website for Diplomat Pharmacy is http://www.diplomatpharmacy.com/.

How can I contact Diplomat Pharmacy?

Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected]


MarketBeat Community Rating for Diplomat Pharmacy (NYSE DPLO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  325 (Vote Outperform)
Underperform Votes:  349 (Vote Underperform)
Total Votes:  674
MarketBeat's community ratings are surveys of what our community members think about Diplomat Pharmacy and other stocks. Vote "Outperform" if you believe DPLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DPLO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel